(01)Overview
Retatrutide (LY3437943) is a single-molecule agonist of three incretin and metabolic receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Its tri-receptor profile makes it a subject of active investigation in metabolic, energy-expenditure, and hepatic lipid research.
Published clinical-stage literature (e.g. Jastreboff et al., NEJM 2023) has examined retatrutide in the context of metabolic regulation; it remains an investigational compound and is not approved for any therapeutic use.
Each Darkside Labs vial is filled to a verified mass, lyophilized for stability, sealed under sterile conditions, and traceable to a batch Certificate of Analysis.
Research areas
- Metabolic & weight-regulation research
What retatrutide is
Retatrutide (LY3437943) is a synthetic peptide developed as a single molecule that activates three receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). A fatty-acid side chain promotes binding to serum albumin, which is what gives the molecule its extended half-life in published pharmacokinetic studies.
Why researchers study it
Most incretin research compounds act on one or two of these receptors. A tri-agonist lets a lab compare GIPR, GLP-1R and GCGR signalling with a single reference compound, which is why retatrutide appears in metabolic, energy-expenditure and hepatic lipid research. Typical in-vitro work includes receptor-binding and cAMP-accumulation assays in cell lines expressing each receptor.
Regulatory status
Retatrutide is an investigational compound. Clinical-stage findings have been published (for example Jastreboff et al., NEJM 2023), but it is not approved for any therapeutic use. Darkside Labs supplies it strictly as a research material for laboratory work.






